TME Pharma signs binding exclusive negotiation agreement with Japan's TMS for NOX-A12 rights

TME Pharma N.V. signed a binding exclusive negotiation agreement with Japanese company TMS Co., Ltd. for its candidate NOX-A12, targeting approximately €10 million in upfront and near-term cash and shares in exchange for worldwide rights to the therapy.

Detected & updated continuously · Source: Nebula